Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | VHL | P40337 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LIPC | P11150 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664040 | 0.87 | POLB (0.56) | EPHX2VHLPOLBUSP2HCAR2 | |
| SCHEMBL21023373 | 0.83 | LMNA (0.59) | EPHX2VHLPOLBUSP2KMT2A | |
| SCHEMBL6403162 | 0.82 | POLB (0.54) | EPHX2POLBUSP2KMT2AALDH1A1 | |
| SCHEMBL27232984 | 0.81 | EPHX2 (0.40) | EPHX2VHLPOLBUSP2KMT2A | |
| SCHEMBL4009973 | 0.80 | SMN1; SMN2 (0.48) | POLBALDH1A1SMN1; SMN2MAPK1NPC1 | |
| SCHEMBL8235172 | 0.79 | EPHX2 (0.49) | EPHX2VHLPOLBUSP2KMT2A | |
| SCHEMBL4017999 | 0.79 | IGF1R (0.44) | EPHX2POLBKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4013192 | 0.79 | EPHX2 (0.44) | EPHX2POLBKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6402461 | 0.78 | PPARA (0.49) | EPHX2POLBKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL314832 | 0.77 | VHL (0.65) | EPHX2VHLPOLBUSP2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-7504420-B2 | Compounds which inhibit beta-secretase activity and methods of use | COMENTIS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1954276-A2 | INDOLE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1871739-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007061763-A2 | INDOLE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006110668-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | EPHX2 2029/4885VHL 575/4885POLB 4840/4885 |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | EPHX2 1188/4885VHL 3371/4885POLB 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.